Gene · 1452
Papers2,578
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,578
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Assessing the Therapeutic Impacts of HAMLET and FOLFOX on BRAF-Mutated Colorectal Cancer: A Study of Cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo. | Medicina (Kaunas) | 2024 | 38256402 | PubTator, text mining | PubMed |
| Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review. | Int J Mol Sci | 2024 | 38255778 | PubTator, text mining | PubMed |
| Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection. | Cancers (Basel) | 2024 | 38254762 | PubTator, text mining | PubMed |
| Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs. | Exp Hematol Oncol | 2024 | 38254219 | PubTator, text mining | PubMed |
| Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. | Nat Commun | 2024 | 38228616 | PubTator, text mining | PubMed |
| Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors. | ACS Chem Biol | 2024 | 38193430 | PubTator, text mining | PubMed |
| LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated β-catenin dephosphorylation in a subset of stem-like bladder cancer cells. | BMC Med | 2024 | 38191448 | PubTator, text mining | PubMed |
| Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes. | Ther Adv Hematol | 2024 | 38186638 | PubTator, text mining | PubMed |
| R-spondin-1 induces Axin degradation via the LRP6-CK1ε axis. | Cell Commun Signal | 2024 | 38183076 | PubTator, text mining | PubMed |
| Non-canonical non-genomic morphogen signaling in anucleate platelets: a critical determinant of prothrombotic function in circulation. | Cell Commun Signal | 2024 | 38172855 | PubTator, text mining | PubMed |
| Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores. | J Med Chem | 2024 | 38170610 | PubTator, text mining | PubMed |
| Induced protein degradation for therapeutics: past, present, and future. | J Clin Invest | 2024 | 38165043 | PubTator, text mining | PubMed |
| TNF-α-induced down-regulation of type I interferon receptor contributes to acquired resistance of cervical squamous cancer to Cisplatin. | J Antibiot (Tokyo) | 2024 | 38102186 | PubTator, text mining | PubMed |
| A Systems Biology Approach to Understand the Racial Disparities in Colorectal Cancer. | Cancer Res Commun | 2024 | 38051091 | PubTator, text mining | PubMed |
| LncRNA-CCAT5-mediated crosstalk between Wnt/β-Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activity. | Cancer Commun (Lond) | 2024 | 38010289 | PubTator, text mining | PubMed |
| WNT Signaling in Stem Cells: A Look into the Non-Canonical Pathway. | Stem Cell Rev Rep | 2024 | 37804416 | PubTator, text mining | PubMed |
| CSNK1A1/CK1α suppresses autoimmunity by restraining the CGAS-STING1 signaling. | Autophagy | 2024 | 37723657 | PubTator, text mining | PubMed |
| Fantastic voyage: The journey of NLRP3 inflammasome activation. | Genes Dis | 2024 | 37692521 | PubTator, text mining | PubMed |
| WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. | Genes Dis | 2024 | 37692481 | PubTator, text mining | PubMed |
| Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance. | Genes Dis | 2024 | 37588226 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1452/papers?page=8